Skip to main content
E

EirGenix, Inc. — Investor Relations & Filings

Ticker · 6589 TW Manufacturing
Open in API
Filings indexed 16 across all filing types
Latest filing 2026-05-04 Regulatory Filings
Country TW Taiwan
Listing TW 6589

About EirGenix, Inc.

http://www.eirgenix.com

EirGenix, Inc. operates under a dual-engine business model, integrating Contract Development and Manufacturing Organization (CDMO) services with the development of proprietary biologics. The company provides comprehensive solutions spanning cell line development, process optimization, analytical testing, and cGMP-compliant manufacturing for both mammalian and microbial cultures. Its technical infrastructure includes large-scale production capabilities with multiple 2,000-liter single-use bioreactors and advanced continuous manufacturing platforms. EirGenix’s internal pipeline focuses on high-quality biosimilars, notably HER2-targeted therapies for breast cancer, including Trastuzumab biosimilar assets. Additionally, the company produces specialty products such as the CRM197 carrier protein and diagnostic tools. By leveraging integrated development and manufacturing expertise, EirGenix delivers cost-effective biopharmaceutical solutions to support global healthcare needs.

Recent filings

Filing Released Lang Actions
本公司民國115年第一季財務報告 之董事會預計召開日期為民國115年05月12日
Regulatory Filings
2026-05-04 Chinese
115年04月法人說明會簡報 — 658920260429E001.pdf
Regulatory Filings
2026-04-29 Chinese
115年04月法人說明會簡報 — 658920260429M001.pdf
Investor Presentation Classification · 1% confidence The document is a slide-based presentation (“EirGenix” corporate deck) covering Q1 revenue breakdown, product pipeline developments, technology platforms, market outlook, and strategic initiatives, ending with “End of the Presentation Q&A.” It is designed for investors, with detailed financial metrics, business updates, and growth strategy, matching the characteristics of an Investor Presentation rather than an earnings release or regulatory announcement.
2026-04-29 Chinese
115年04月法人說明會簡報
Investor Presentation Classification · 1% confidence The document is a notice listing a corporate “法人說明會” (institutional investor presentation) event with date, time, location, and links to PDF presentation materials (“法人說明會簡報內容”). It is not an earnings release or regulatory filing, but clearly pertains to an investor presentation session. Therefore it best fits the “Investor Presentation” category (IP).
2026-04-29 Chinese
115年年報及股東會資料 — 2026_6589_20260529FE2.pdf
AGM Information Classification · 1% confidence The document is titled “Handbook for 2026 Annual Shareholders' Meeting” and contains the full meeting agenda, proposed resolutions, report items (business report, audit committee review, remuneration, financial statements), and attachments such as articles of incorporation and rules of procedure. It is clearly the informational and presentation materials distributed for an Annual General Meeting rather than a standalone annual or quarterly report, earnings release, proxy solicitation form, or other regulatory filing. This matches the definition of AGM Information (Code: AGM-R).
2026-04-28 English
115年年報及股東會資料 — 2026_6589_20260529F02.pdf
Regulatory Filings
2026-04-28 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.